Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diffuse large B-cell lymphoma recurrent
0.020 Biomarker disease BEFREE Hence, the use of T22-GFP-H6 nanocarrier could be a good strategy to load and deliver drugs or toxins to treat specifically CXCR4-mediated refractory or relapsed diffuse large B-cell lymphoma without systemic toxicity. 31248974 2020
Diffuse large B-cell lymphoma recurrent
0.020 GeneticVariation disease BEFREE <b>Methods:</b> Six patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54 ± 8 y) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation. 29777009 2019